Thank you

This live web event has ended. Thank you for attending.

Description

Dr. Jason Goldman is an infectious disease physician, epidemiologist, and clinical researcher who has been an investigator in multiple clinical trials evaluating different therapies in the treatment of COVID-19 during the pandemic. He will provide an overview of the current treatment landscape for patients who have been hospitalized with COVID-19 as recommended by the NIH COVID-19 Treatment Guidelines, including remdesivir, dexamethasone, baricitinib, and tocilizumab1. Key data from pivotal clinical trials of these drugs, including time to recovery, mortality, and safety, will be discussed, providing the evidence base for their use in hospitalized COVID-19 patients.

This program is sponsored by Eli Lilly and Company. An archive recording will not be made available for this webinar.

By registering for this webinar, you agree your information will be shared with the sponsor.

No CME or MOC credits are available for this program.

Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.